Insider Trading & Ownership of James B. Breitmeyer

Summary
The estimated net worth of James B. Breitmeyer is at least $372,788 dollars as of 01 May 2026. James B. Breitmeyer is the Chief Executive Officer, Director of Oncternal Therapeutics, Inc. and owns shares of Oncternal Therapeutics, Inc. stock worth about $325.3K. James B. Breitmeyer is the Director of Vaxart, Inc. and owns shares of Vaxart, Inc. (VXRT) stock worth about $47.5K.
Signature
/s/ Edward Berg, attorney-in-fact for James B. Breitmeyer
All Insider Reports
All Insider Reports

Follow Filing Activity

Follow James B. Breitmeyer and return when a new Insider Trading filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.

Create free account and return here Already have an account? Sign in and return here

Key facts

  • James B. Breitmeyer has 4 issuer positions tracked on this page.
  • Estimated disclosed ownership value: $372,788.
  • Recent insider filing activity is available below.

Change

  • Largest disclosed position: Oncternal Therapeutics, Inc. ($325,311).
  • Past-year value change for that position: .

Research use

  • This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
  • You can cross-check role, issuer, and filing chronology directly against the SEC source.

Evidence

Filed on Form 4

Insider ownership context is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Ownership of James B. Breitmeyer

VXRT Forms 3/4/5

Vaxart, Inc.

Relationship
Director
Holdings value
$47,477
Past year net change
Change %
Report period
23 Apr 2026
OTIC Forms 3/4/5

OTONOMY, INC.

Relationship
Director
Holdings value
Past year net change
Change %
Report period
21 Jun 2022
ZGNX Forms 3/4/5

ZOGENIX, INC.

Relationship
Director
Holdings value
Past year net change
Change %
Report period
07 Mar 2022

Insider Transactions Reported by James B. Breitmeyer:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .